As of 2026-05-24, the Intrinsic Value of Sun Pharma Advanced Research Co Ltd (SPARC.NS) is 9,496.67 INR. This SPARC.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 209.77 INR, the upside of Sun Pharma Advanced Research Co Ltd is 4,427.20%.
The range of the Intrinsic Value is 8,597.54 - 10,635.00 INR
Based on its market price of 209.77 INR and our intrinsic valuation, Sun Pharma Advanced Research Co Ltd (SPARC.NS) is undervalued by 4,427.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 8,597.54 - 10,635.00 | 9,496.67 | 4427.2% |
| DCF (Growth 10y) | 9,347.65 - 11,437.00 | 10,276.84 | 4799.1% |
| DCF (EBITDA 5y) | 13,853.37 - 20,034.17 | 17,697.02 | 8336.4% |
| DCF (EBITDA 10y) | 11,821.27 - 16,511.44 | 14,409.98 | 6769.4% |
| Fair Value | 1,196.54 - 1,196.54 | 1,196.54 | 470.40% |
| P/E | 1,136.23 - 50,110.77 | 21,157.90 | 9986.2% |
| EV/EBITDA | 494.70 - 24,842.16 | 11,571.62 | 5416.3% |
| EPV | (78.05) - (89.89) | (83.97) | -140.0% |
| DDM - Stable | 165.96 - 269.39 | 217.68 | 3.8% |
| DDM - Multi | 4,952.15 - 6,546.86 | 5,653.43 | 2595.1% |
| Market Cap (mil) | 68,074.56 |
| Beta | 1.69 |
| Outstanding shares (mil) | 324.52 |
| Enterprise Value (mil) | 73,656.06 |
| Market risk premium | 8.31% |
| Cost of Equity | 18.59% |
| Cost of Debt | 9.54% |
| WACC | 18.24% |